Shire Targets Roxane, Watson Over Generic Vyvanse

Law360, New York (July 7, 2011, 1:02 PM EDT) -- Shire PLC announced Thursday it had filed patent infringement suits against Roxane Laboratories Inc. and Watson Laboratories Inc. in New Jersey and California in an effort to protect the market for attention deficit hyperactivity disorder treatment Vyvanse.

Both the New Jersey case against Boehringer Ingelheim Corp. unit Roxane and the California case against Watson were triggered by the defendants' bids for a green light from the U.S. Food and Drug Administration to make their own versions of the drug.

“The lawsuits were initiated in response to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.